Cagrilintide

Cagrilintide is a long-acting analogue of amylin. It is being tested to treat obesity and type 2 diabetes by itself and in combination with semaglutide as cagrilintide/semaglutide.

Research

A systematic review and metanalysis of cagrisema, published in 2024, found that cagrisema may provide weight loss benefits.